Gufic Biosciences · NSE: GUFICBIO · BSE: 509079
Q1 FY21 results · Apr–Jun 2020
Gufic Biosciences reported revenue from operations of ₹54.14 crore (down 41.4% from Q1 FY20) and net loss of ₹3.75 crore for Q1 FY21 (Apr–Jun 2020), on a standalone basis.
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 54.14 | 92.39 | −41.4% | 81.59 | −33.6% |
| Other income | 0.99 | 1.02 | −3.2% | 1.13 | −12.1% |
| Total income | 55.13 | 93.41 | −41.0% | 82.72 | −33.3% |
| Profit before tax | (5.11) | 9.19 | Turned loss | 6.07 | Turned loss |
| Net profit for the period | (3.75) | 6.81 | Turned loss | 4.72 | Turned loss |
| EPS, basic (₹) | (0.48) | 0.88 | Turned loss | 0.61 | Turned loss |
| Net margin (%) | -6.9 | 7.4 | 5.8 |
Standalone
- Filed with BSE
- 16 Sep 2020, 00:27 IST
- Board meeting
- 14 Sep 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE